Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (January 2025)
21 slides from Mimedx's investor presentation, Jan 14, 2025
Slide 1: Investor Presentation January 2025
Exhibit 99.1 Investor Presentation January 2025
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: A Pioneer and Leader Focused on Helping Humans Heal
A Pioneer and Leader Focused on Helping Humans Heal Our vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. Over a decade of experience Leading the industry with Poised to capitalize on favorable helping clinicians manage chronic
Slide 4: The Most Comprehensive End-to-End Product Ecosystem
The Most Comprehensive End-to-End Product Ecosystem New product innovations leading to untapped opportunities The most studied for growth, including an portfolio of placental increasing footprint in products with 50+ clinical the Surgical market. & scientific publications and over 300 million payer
Slide 5: Commercial Scale, Leverage & Extensive Reach
Commercial Scale, Leverage & Extensive Reach 3+ Over 200 direct sales Over 75 agencies Robust corporate Extensive commercial Experience selling Growing presence professionals with 200+ agents support network coverage with over 300 more than 3 million in Japan nationwide nationwide million payer live
Slide 6: Expansive Donor Network & IP Power
Expansive Donor Network & IP Power Our Product Offering National Network of Birthing Center Partners Proprietary Processing Backed by Broad Portfolio of Intellectual Property Expectant Mothers Delivery of Healthy Proprietary Processing & Shelf-Stable, Packaged Product Consent for Introduced to Donat
Slide 7: Addressing a Large and Unmet Need for Healing Solutions
Addressing a Large and Unmet Need for Healing Solutions Favorable Demographic Trends Increasing Clinical Evidence Expanding Potential For Products Ineffective Wound Advances Driving Emerging 10+ ~16% Management Leads to Improved Outcomes Opportunities in Poor Outcomes for Wound Patients Surgical Set
Slide 8: Increasing Awareness of Massive Potential for Placental Tissue
Increasing Awareness of Massive Potential for Placental Tissue October 10, 2024 Her Face Was Unrecognizable After an Explosion. A Placenta Restored It. “Research has found placenta-derived grafts can reduce pain and inflammation, heal burns, prevent the formation of scar tissue and adhesions around
Slide 9: Large Wound Care Business with Growing Surgical Footprint
Large Wound Care Business with Growing Surgical Footprint LTM Wound Performance LTM Surgical Performance* LTM Sales Mix by $250,000 $250,000 Product Type +14% $200,000 $200,000 $150,000 $150,000 34% +12% 66% $100,000 $100,000 $50,000 $50,000 $0 $0 Wound LTM @ Q3:23 LTM @ Q3:24 LTM at Q3:23 LTM @ Q3:
Slide 10: Evolving Strategic Priorities Heading into 2025
Evolving Strategic Priorities Heading into 2025 1 2 3 Innovate & Diversify Develop & Deploy Enhance Customer Product Portfolio to Programs to Expand Intimacy Maximize Growth Surgical Footprint Maximize opportunity Leverage existing Continue to build out for EPIFIX & EPICORD evidence for surgical cus
Slide 11: Best-In-Class Human Allograft Wound Products
Best-In-Class Human Allograft Wound Products Flagship products with multiples sizes and Lyophilized human placental allograft membrane configurations available for differing wound types Includes the amnion layer, intermediate layer, and chorion Backed by industry-leading RCT data layer Extensive com
Slide 12: The Patient Journey in Wound Care
The Patient Journey in Wound Care MIMEDX products are available in all settings where patients receive care… Wound Assisted …and other Private Mobile Hospital Nursing Hospital Home Living Care care Office Health Inpatient Facility Outpatient Health Clinic Facility settings …and are used on a range o
Slide 13: Expanding & Innovative Offering for Surgical Market
Expanding & Innovative Offering for Surgical Market Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Products HELIOGEN augments our pipeline through Solutions strategic portfolio expansion Deep/tunneling, ✓ irregular-shaped defects Soft tissue deficit First xenog
Slide 14: Building Library of Evidence for Surgical Applications
Building Library of Evidence for Surgical Applications Recent Publications Showcase Breadth of Potential Use Cases for MIMEDX Products in Surgery Neuro EPIFIX® in Mohs Procedures Cranioplasty Procedures with AMNIOFIX® 1 4 Mohs Clinical Outcomes with Conventional Methods Peer-reviewed Retrospective S
Slide 15: Studies in Process Focused on Significant Surgical Opportunities
Studies in Process Focused on Significant Surgical Opportunities AMNIOFIX in AMNIOFIX in AMNIOFIX in EPIFIX Mohs HECON GI Anastomosis Liver Transplant Breast Reduction Accepted for Publication Manuscript Pending RCT Enrollment Underway RCT Enrollment Underway EPIFIX used in Mohs procedures Wound bre
Slide 16: Diversified Customer Base
Diversified Customer Base Site of Service Segment Commentary Hospitals & Stable reimbursement settings and 55% Wound Care growing with expanded use of products Clinics in surgical applications 32% Medicare reimbursement evolving, Private Office resulting in opportunity for EPIFIX & EPICORD Derived f
Slide 17: Maturing Medicare Reimbursement Underway
Maturing Medicare Reimbursement Underway Worsening Medicare Spending Crisis Underscores Need for Overhaul in Wound Care 1 Medicare Allowed Charges for skin substitutes have exploded since 2020 resulting in Recent Medicare abuses in private office and run rate spend of over $1 billion of spend PER MO
Slide 18: Financial Highlights
Financial Highlights Quarterly Net Cash Balance $70MM LTM Net Sales LTM Gross Margin $343MM 83% +11% year-over-year $50MM $34MM $32MM 1 $29MM LTM Adjusted EBITDA LTM GAAP Net Income $20MM $78MM $88MM 23% of net sales Q2:23 Q3:23 Q4:23 Q1:24 Q2:24 Q3:24 Cash Balance LTM Free Cash Flow Strong & improv
Slide 19: Full Year 2024 and Long-Term Financial Goals
Full Year 2024 and Long-Term Financial Goals* Committed to delivering sustained growth and profitability in the short- and long-term Full Year Long-Term 2024 Net Sales High single-digits Low double-digits % Growth vs. 2023 Profitability Adjusted EBITDA Margin Above 20% *As disclosed on our Third Qua
Slide 20: Experienced, Skillful Leadership Team Executing Strategy
Experienced, Skillful Leadership Team Executing Strategy Management Team with Track Record of Success in MedTech Prior Roles Include: Doug Rice Joe Capper Butch Hulse Chief Financial Chief Executive Chief Administrative Officer Officer Officer & General Counsel Kim Moller John Harper, Ph.D. Ricci Wh
Slide 21: Conclusion
Conclusion 1 Large & expanding addressable markets 2 Maturing reimbursement & regulatory landscape 3 Competitive advantage with defensible IP and proprietary technology 4 Strong & improving financial profile & balance sheet 5 Experienced & skillful leadership team more than capable of executing stra